These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 28387542)

  • 1. The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease.
    Nathan AS; Sen S; Yeh RW
    Expert Opin Drug Saf; 2017 May; 16(5):561-572. PubMed ID: 28387542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates in antiplatelet agents used in cardiovascular diseases.
    Cheng JW
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):514-24. PubMed ID: 24213473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
    Packard KA; Campbell JA; Knezevich JT; Davis EM
    Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and future antiplatelet therapies: emphasis on preserving haemostasis.
    McFadyen JD; Schaff M; Peter K
    Nat Rev Cardiol; 2018 Mar; 15(3):181-191. PubMed ID: 29297508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet Function Testing: A Role for Personalised Therapy in Coronary Disease.
    Farag M; Gorog DA
    Curr Pharm Des; 2017; 23(9):1315-1327. PubMed ID: 28137225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of platelet reactivity testing in patients on antiplatelet therapy for prediction of bleeding events after cardiac surgery.
    Leunissen TC; Janssen PW; Ten Berg JM; Moll FL; Korporaal SJ; de Borst GJ; Pasterkamp G; Urbanus RT
    Vascul Pharmacol; 2016 Feb; 77():19-27. PubMed ID: 26724555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response variability to P2Y12 receptor inhibitors: expectations and reality.
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
    Faxon DP
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications.
    Goli RR; Contractor MM; Nathan A; Tuteja S; Kobayashi T; Giri J
    Curr Atheroscler Rep; 2017 Nov; 19(12):56. PubMed ID: 29103068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological inhibition of platelet reactivity. Clinical and pharmacodynamic effects.
    Vallés J; Moscardo A; Madrid I; Santos MT
    Curr Vasc Pharmacol; 2013 Jul; 11(4):431-47. PubMed ID: 23905638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet effect of aspirin in patients with coronary artery disease.
    Grove EL
    Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
    Islam AM; Patel PM
    J Cardiovasc Pharmacol; 2010 Jun; 55(6):585-94. PubMed ID: 20224426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet agents in hemodialysis.
    Migliori M; Cantaluppi V; Scatena A; Panichi V
    J Nephrol; 2017 Jun; 30(3):373-383. PubMed ID: 27928736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticagrelor: a review of its use in adults with acute coronary syndromes.
    Dhillon S
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):51-68. PubMed ID: 25672642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bridging: Perioperative management of chronic anticoagulation or antiplatelet therapy].
    Nowak-Göttl U; Langer F; Limperger V; Mesters R; Trappe RU
    Dtsch Med Wochenschr; 2014 Jun; 139(24):1301-6. PubMed ID: 24892468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing post-treatment platelet reactivity: a focus on patient selection and setting.
    Laine M; Frere C; Ronsin O; Gaubert M; Toesca R; Bessereau J; Michelet P; Gramond C; Helal O; Paganelli F; Bonello L
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1557-66. PubMed ID: 23992465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.
    Macaulay TE; Allen C; Ziada KM
    Expert Opin Pharmacother; 2010 Apr; 11(6):1015-22. PubMed ID: 20307225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.